...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder
【24h】

Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder

机译：表皮生长因子受体和c-erbB-2蛋白表达在上尿路移行细胞癌中对膀胱癌复发的意义

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

An immunohistochemical study of the expression of epidermal growth factor receptor (EGFR) and c-erbB-2 protein was performed in fresh-frozen sections from 30 patients with transitional cell cancers (TCCs) of the upper urinary tract (15 renal pelvic cancers, 15 ureteral cancers) who underwent total nephroureterectomy. We followed them and examined whether TCC appeared in the urinary bladder. The follow-up period ranged from 116 to 2348 days (mean 666 days). The mean period until a secondary urinary bladder cancer appeared was 306 days (116-829 days). Thirteen of those 30 TCCs (43.3%) showed increased expression of EGFR, and 11 TCCs (36.7%) showed increased expression of c-erbB-2. In 12 of 30 patients (40.0%), a secondary urinary bladder cancer appeared after surgery. In only one of the ten patients (10.0%) whose tumours did not exhibit increased expression of either of these receptors the tumour recurred in bladder. On the other hand, in 11 of 20 (55.0%) patients whose tumours had increased EGFR and/or c-erbB-2 expression, secondary urinary bladder cancers recurred after surgery (P < 0.05). Thus, the recurrence rate of TCCs with increased EGFR and/or c-erbB-2 expression was significantly higher than that of tumours showing no increased expression of these receptors (P < 0.01). These results suggest that the immunohistochemical detection of the expression of EGFR and c-erbB-2 in urothelial cancers of the upper urinary tract might be a useful method for determining the likelihood of secondary bladder cancer recurrences.
机译：对30例上尿路移行细胞癌（TCC）患者（15例肾盂癌，15例新鲜冷冻）的新鲜冰冻切片进行了表皮生长因子受体（EGFR）和c-erbB-2蛋白表达的免疫组织化学研究。输尿管癌）。我们跟踪他们，检查TCC是否出现在膀胱中。随访期为116至2348天（平均666天）。直到出现继发性膀胱癌的平均时间为306天（116-829天）。在这30个TCC中，有13个（43.3％）显示EGFR表达增加，在11个TCC中（36.7％）显示c-erbB-2表达增加。 30名患者中的12名（40.0％），术后出现继发性膀胱癌。在肿瘤未表现出这些受体之一表达增加的十名患者中，只有一名（10.0％），该肿瘤在膀胱中复发。另一方面，在20例（55.0％）肿瘤中EGFR和/或c-erbB-2表达增加的患者中，继发性膀胱癌在手术后复发（P <0.05）。因此，EGFR和/或c-erbB-2表达增加的TCC的复发率显着高于未显示这些受体表达增加的肿瘤的复发率（P <0.01）。这些结果表明，免疫组化检测上尿路尿路上皮癌中EGFR和c-erbB-2的表达可能是确定继发性膀胱癌复发可能性的有用方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号